3 ms·
Yes, it definitely could be this which is why I said "my gut suspects the arduous FDA approval process." This could be the source of a lot of that fixed cost. I
by harryh 9y ago
Yes, it definitely could be this which is why I said "my gut suspects the arduous FDA approval process." This could be the source of a lot of that fixed cost. I'd be generally curious to see data on what is involved in starting up a new production line for these kinds of pills.
Is there a chemist in the house? :)
- gizmo 9y agohttps://dailyreckoning.com/generic-bioequivalence-and-outrageous-profits-in-biotech/ https://dailyreckoning.com/generic-bioequivalence-and-outrag... Look for the explanation by Derek Lowe in the linked article. Key points: > The FDA grants market exclusivity to companies that are willing to take ‘grandfathered’ compounds into compliance with their current regulatory framework.” Once a company does that, it gains an effective monopoly through the "generic bioequivalence" rules. Setting up the production line isn't the issue, because the pharmaceutical company will outsource the actual manufacturing of the drugs anyway.